Methadone

1. 2026-10-19issueIssued info_card
2. 2026-09-14revisionr1.a1
3. 2026-09-07srcMedications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose: A Review.
4. 2026-09-07srcBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
5. 2026-09-07srcMethadone maintenance therapy versus no opioid replacement therapy for opioid dependence.
6. 2026-09-07srcMethadone for chronic non-cancer pain in adults.
7. 2026-09-07srcMethadone for neuropathic pain in adults.
8. 2026-09-07srcPopulation Pharmacokinetics of Intravenous Methadone Enantiomers in Adults: A Comprehensive Model.
9. 2026-09-07srcPharmacokinetic modeling of R and S-Methadone and their metabolites to study the effects of various covariates in post-operative children.
10. 2026-09-07srcOpioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects
11. 2026-09-07srcCharacterizing post-mortem blood concentrations in methadone-related deaths.
12. 2026-09-07srcSerotonin syndrome and pain medication: What is relevant for practice?
13. 2026-09-07srcComparison of the effects of methadone and heroin on human ether-à-go-go-related gene channels.
14. 2026-09-07srcRespiratory effects of diazepam/methadone combination in rats: a study based on concentration/effect relationships.
15. 2026-09-07srcEvaluation of poly-drug use in methadone-related fatalities using segmental hair analysis
16. 2026-09-07srcThe Impact of CYP2D6 metabolizer phenotypes on the EDDP/methadone metabolic ratio: A comprehensive analysis.
17. 2026-09-07srcCardiovascular Complications of Opioid Use: JACC State-of-the-Art Review.
18. 2026-09-07srcAssociation of the D-amino acid oxidase gene with methadone dose in heroin dependent patients under methadone maintenance treatment.
19. 2026-09-07srcNeurobiologic Advances from the Brain Disease Model of Addiction.
20. 2026-09-07srcTell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities.
21. 2026-09-07srcQTc prolongation and torsades de pointes (TdP) in individuals undergoing methadone maintenance treatment (MMT): A systematic review and meta-analysis.
22. 2026-09-07srcOpioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome
23. 2026-09-07srcA systematic review of opioid conversion ratios used with methadone for the treatment of pain.
24. 2026-09-07srcMortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
25. 2026-09-07srcDrug-Induced Arrhythmias: A Scientific Statement From the American Heart Association.
26. 2026-09-07srcCharacterization of methadone as a β-arrestin-biased μ-opioid receptor agonist.
27. 2026-09-07srcHeroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction
28. 2026-09-07srcToward precision prescribing for methadone: Determinants of methadone deposition.
29. 2026-09-07srcMechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block.
30. 2026-09-07srcImplications of OPRM1 and CYP2B6 variants on treatment outcomes in methadone-maintained patients in Ontario.
31. 2026-09-07srcCDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022
32. 2026-09-07srcOpioid receptor desensitization: mechanisms and its link to tolerance.
33. 2026-09-07srcMechanisms of fatal opioid overdose.
34. 2026-09-07srcNeuronal inhibitory effects of methadone are predominantly opioid receptor mediated in the rat spinal cord in vivo.
35. 2026-09-07srcInterindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.
36. 2026-09-07srcA MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE.
37. 2026-09-07srcStereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.
38. 2026-09-07srcFunctional inhibition by methadone of N-methyl-D-aspartate receptors expressed in Xenopus oocytes: stereospecific and subunit effects.
39. 2026-09-07srcEffects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone.
40. 2026-09-07srcMethadone and buprenorphine added to the WHO list of essential medicines.
41. 2026-09-07srcMethadone toxicity fatalities: a review of medical examiner cases in a large metropolitan area.
42. 2026-09-07srcCYP2B6 and OPRM1 gene variations predict methadone-related deaths.
43. 2026-09-07srcKetobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord.
44. 2026-09-07srcThe d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord.
45. 2026-09-07srcOpioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists.
46. 2026-09-07srcThe History of Methadone
47. 2026-09-07srcThe Discovery of Methadone
48. 2026-09-07srcIntroduction: Federal Regulation of Methadone Treatment
49. 2026-09-07srcMethadone - DEA Drug & Chemical Information
50. 2026-09-07srcPubChem Compound: Methadone (CID 4095)
51. 2026-09-04issueIssued emergency
52. 2026-09-04issueIssued info_card
53. 2026-09-04issueIssued notice
54. 2026-07-03proposaldependence · taper
55. 2026-06-04proposal30 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
56. 2026-06-04publicationPublication — backfill
57. 2026-04-27revisionRevision 1
58. 2026-04-27genGeneration — pipeline-v5pipeline-v5
59. 2026-04-27rungeneration run

The same entries, as forms: six forms.